Contextual Genomics launches new liquid biopsy test and updated solid tumor panel

laboratory
Both assays are integrated with molecular bar-coding to provide automated quality-assurance testing. (Pixabay)

Vancouver-based Contextual Genomics has launched two molecular hotspot assays for detecting genomic mutations in blood and solid tumors.

The new version of the company’s Find It solid tumor panel now screens for 146 somatic genome alterations, and 23 exons in 30 cancer-associated genes, to help identify precision cancer treatments and recognize drug-resistant mutations. New additions to the panel include tests for mutations in the POLE gene, which have been associated with colorectal cancer as well as immunodeficiency.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Meanwhile, the new Follow It panel screens for the same mutations in cell-free circulating tumor DNA found in blood plasma. Follow It can be used in patients with widespread metastatic disease at diagnosis, as well as a monitoring tool to gauge tumor burden and treatment resistance. It can also be used to follow disease progression, including in patients initially tested with Find It, according to the company.

Both assays are designed for next-generation sequencing systems and are integrated with proprietary molecular bar-coding techniques to provide automated, centrally monitored quality-assurance testing. In addition, the Find It assay is supported by Contextual Genomics’ cloud-based genome analysis engine.

Suggested Articles

The Tel Aviv-based VC firm focused on digital health has closed a new fund totaling $170 million, with plans to expand to the Asia Pacific region.

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.